Senate Democratic leadership released legislative text on Wednesday detailing their updated drug pricing plans in<b> </b>an attempt to revive the Build Back Better reconciliation bill.
On December 9, join Partner Winston Kirton for a panel titled "Lessons Learned for Medical Products from COVID-19: Enforcement and Compliance Risks and Strategies for Navigating the Future"
US: Can the DPA make a dent in the vaccine supply needs of the COVID-19 pandemic? US President Biden’s team is using the US Defense Production Act (DPA) to launch a full scale “wartime effort” to address the supply chain shortages inherited from the Trump administration.
On a call with BioPharma-Reporter this week, experts in biopharma, life sciences and regulatory matters, Winston Kirton and Reed Stephens from the global law firm of Winston & Strawn, weighed in on what the Biden led team can do under that legislative tool.
The lawyers also spoke about what is being done under the new US administration to cast the net wider in terms of having access to other COVID-19 vaccine candidates beyond those from Pfizer and Moderna, the only vaccines to date, granted emergency use authorization by the US Food and Drug Administration (FDA) for distribution in the US.